Sarepta Therapeutics (SRPT) Equity Average (2011 - 2026)

Sarepta Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Equity Average fell 0.93% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (down 0.93% YoY), while the FY2025 annual figure was $1.3 billion, up 11.78% from the prior year.
• Equity Average was $1.3 billion for Q1 2026 at Sarepta Therapeutics, up from $1.2 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $1.4 billion in Q4 2024 to a low of $407.9 million in Q4 2022.
• Historically, Equity Average has averaged $967.1 million across 5 years, with a median of $910.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Equity Average sank 41.63% in 2022, then jumped 99.03% in 2023.
• A 5-year view of Equity Average shows it stood at $407.9 million in 2022, then jumped by 99.03% to $811.8 million in 2023, then jumped by 69.29% to $1.4 billion in 2024, then dropped by 10.48% to $1.2 billion in 2025, then gained by 7.52% to $1.3 billion in 2026.
• The last three Equity Average figures came in at $1.3 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.